QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:KRYS

Krystal Biotech - KRYS Stock Forecast, Price & News

$72.39
-2.19 (-2.94%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$72.18
▼
$75.92
50-Day Range
$72.39
▼
$84.27
52-Week Range
$47.67
▼
$89.59
Volume
167,914 shs
Average Volume
202,049 shs
Market Capitalization
$1.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$119.25

Krystal Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
64.7% Upside
$119.25 Price Target
Short Interest
Bearish
5.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.61mentions of Krystal Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$7.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.57) to ($2.83) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

182nd out of 986 stocks

Biological Products, Except Diagnostic Industry

25th out of 165 stocks

See Top Rated MarketRank™ Stocks Here

KRYS stock logo

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

March 18, 2023 | americanbankingnews.com
Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Expands By 6.3%
March 6, 2023 | finance.yahoo.com
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
March 22, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
March 6, 2023 | finance.yahoo.com
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
March 3, 2023 | benzinga.com
Krystal Biotech Stock (NASDAQ:KRYS), Guidance and Forecast
March 2, 2023 | finance.yahoo.com
Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
February 28, 2023 | markets.businessinsider.com
Guggenheim Reaffirms Their Buy Rating on Krystal Biotech (KRYS)
February 28, 2023 | markets.businessinsider.com
Expert Ratings for Krystal Biotech
March 22, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
February 28, 2023 | cnbc.com
Buy this little-known biotech stock set to rally nearly 60% as use of gene therapy grows, Goldman Sachs says
February 28, 2023 | markets.businessinsider.com
Krystal Biotech (KRYS) was upgraded to a Buy Rating at Goldman Sachs
February 27, 2023 | msn.com
Krystal Biotech GAAP EPS of -$1.25 misses by $0.26
February 27, 2023 | finance.yahoo.com
Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
January 20, 2023 | seekingalpha.com
Krystal Biotech: Reached My Price Target, Waiting For A Drop
January 18, 2023 | finance.yahoo.com
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
January 10, 2023 | msn.com
FDA extends review of Krystal's topical gene therapy for skin disorder citing manufacturing data
January 9, 2023 | finance.yahoo.com
Krystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDA
January 9, 2023 | markets.businessinsider.com
Krystal Biotech Announces FDA's 3-Month Extension Of BLA PDUFA Date And Regulatory Update For B-VEC
January 9, 2023 | finance.yahoo.com
Krystal Biotech’s stock is down on delayed PDUFA date
January 9, 2023 | finance.yahoo.com
Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
December 16, 2022 | finance.yahoo.com
BofA Securities: The most promising biotech stocks in 2023
December 15, 2022 | finance.yahoo.com
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine
December 14, 2022 | finance.yahoo.com
New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
December 12, 2022 | finance.yahoo.com
12 Best Small-Cap Healthcare Stocks To Buy Now
December 6, 2022 | finance.yahoo.com
2 Risky Stocks That Could Soar in 2023
December 5, 2022 | finance.yahoo.com
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
December 1, 2022 | finance.yahoo.com
Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings
2/27/2023
Today
3/22/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
CUSIP
N/A
CIK
1711279
Web
www.krystalbio.com
Phone
(412) 586-5830
Fax
N/A
Employees
119
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$119.25
High Stock Price Forecast
$133.00
Low Stock Price Forecast
$101.00
Forecasted Upside/Downside
+64.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.51)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-139,980,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-21.19%
Return on Assets
-19.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.30
Quick Ratio
13.30

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$20.28 per share
Price / Book
3.57

Miscellaneous

Outstanding Shares
25,760,000
Free Float
21,178,000
Market Cap
$1.86 billion
Optionable
Not Optionable
Beta
0.87

Social Links


Key Executives

  • Krish S. Krishnan
    Chairman, President & Chief Executive Officer
  • Suma M. KrishnanSuma M. Krishnan
    Director, President-Research & Development
  • George Chen
    Manager-Information Technology & CSV
  • Trevor Parry
    Senior Director-Scientific Affairs
  • David Glynn
    General Counsel & Head-Commercial & Compliance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.

What is Krystal Biotech's stock price forecast for 2023?

4 brokerages have issued 12 month price objectives for Krystal Biotech's shares. Their KRYS share price forecasts range from $101.00 to $133.00. On average, they anticipate the company's stock price to reach $119.25 in the next year. This suggests a possible upside of 64.8% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2023?

Krystal Biotech's stock was trading at $79.22 at the beginning of the year. Since then, KRYS stock has decreased by 8.6% and is now trading at $72.37.
View the best growth stocks for 2023 here.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 1,190,000 shares, an increase of 6.3% from the February 13th total of 1,120,000 shares. Based on an average daily trading volume, of 189,800 shares, the days-to-cover ratio is presently 6.3 days. Approximately 5.7% of the company's shares are sold short.
View Krystal Biotech's Short Interest.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our KRYS earnings forecast.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings results on Monday, February, 27th. The company reported ($1.25) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.01.

What ETFs hold Krystal Biotech's stock?

ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Harbor Disruptive Innovation ETF (INNO).

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a number of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (5.48%), Lord Abbett & CO. LLC (4.96%), Frazier Life Sciences Management L.P. (3.88%), Credit Suisse AG (2.65%), Point72 Asset Management L.P. (2.16%) and First Light Asset Management LLC (1.84%). Insiders that own company stock include Dino A Rossi, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $72.37.

How much money does Krystal Biotech make?

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $1.86 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.51) on an earnings per share basis.

How many employees does Krystal Biotech have?

The company employs 119 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 3/22/2023 by MarketBeat.com Staff